Gooding Medical, a pharmacy chain that sells medical products to people, has come under fire after its logo appeared on several different medical products in the United States, including prescription painkillers and anti-inflammatories.
“Gooding Medical is committed to providing safe and effective care for our customers,” a company spokesperson told CBC News.
“We are committed to using the highest standards of quality, transparency and safety.”
The company’s logo was removed from two of its drug labels, one for anti-inflammatory OxyContin and the other for OxyContin, Oxycontin XR and OxyContin Ultra, in the U.S. last week.
The other OxyContin labels were updated last week with the words “Made in the USA,” which has since been replaced by the words, “Made by Gooding.”
Gooding has not responded to requests for comment from CBC News about the change in its branding.
One product called OxyContin XR, which is approved by Health Canada for use in the treatment of severe pain and is marketed under the brand name “Opioid-Suppressed,” is available in Canada under a different name, “Medicated for Pain,” but the company is still selling the product under the “Opiate-Suppression” brand.
“The Gooding medical logo has been used on some OxyContin products for a long time and is not consistent with our vision of a medical brand,” a spokesperson for Gooding told CBC.
“As such, we have removed the Gooding medicated label from OxyContin drugs sold in the US and will be discontinuing the OxyContin medicated OxyContin product in the coming weeks.”
A spokesperson for Health Canada told CBC it’s not the first time the company has made a name for itself with a logo that does not conform to the health and safety standards of its product.
“For example, we also used a logo from the United Kingdom which is not a health-care product and we had to remove it because of the high risk associated with the use of it,” the spokesperson said.
“This is not an issue that we have faced with our product in other countries.
It’s not something that we’ve ever had to deal with with.”
Goodeing has been involved in health and human services since 2002, when it was formed as a subsidiary of Johnson & Johnson, a pharmaceutical giant that has since changed its name to Pfizer.
The company is known for its high-end medical products.
The brand has won numerous awards, including the American Psychological Association’s prestigious Gooding Award for its innovative marketing.
The Gooding brand has been synonymous with OxyContin since the 1970s, when the company created OxyContin OxyContin XL and Oxycontin OxyContin DX, a line of OxyContin pills that were available for prescription.
OxyContin was a popular brand for people in the early 1970s and ’80s, especially in the pharmaceutical industry.
In the early 1980s, a group of doctors from the University of Pennsylvania Medical Center wrote an open letter to the company asking it to stop selling OxyContin.
The doctors also wrote a letter of support for Oxycontin during its history, including a statement by the company’s founder and CEO, Dr. Robert Gooding, in 1973 that OxyContin had been developed to be “a drug for pain relief and not as a narcotic.”
In response, the company pulled the brand from its packaging and began to market OxyContin under the name “Medication for Pain.”
The brand became the most widely sold prescription painkiller in the world in the 1980s.
“It was a very popular drug,” said Dr. James Gooding Jr., the president of the University at Buffalo Medical Center.
“A lot of people got addicted to it, and there was a lot of abuse.
It became a drug of abuse.”
OxyContin has remained in the drug supply chain, with the U